Depomed, Inc. (NASDAQ: DEPO) today announced that it has entered into a definitive agreement to acquire the U.S. rights to the NUCYNTA franchise from Janssen Pharmaceuticals, Inc. for $1.05 billion. The NUCYNTA franchise includes NUCYNTA® ER (tapentadol) extended release tablets indicated for the management of pain, and NUCYNTA® (tapentadol), an immediate release version of tapentadol. The deal will make NUCYNTA the flagship asset in Depomed’s growing portfolio of pain and neurology specialty pharmaceuticals. More >>

Simpson Thacher represented Riverwood Capital Partners in connection with the organization of Riverwood Capital Partners II, L.P., an approximately $1.25 billion private equity fund focused on making equity-related growth investments in middle-market companies, primarily in the technology and services industries, seeking capital to achieve growth and profitability on a global scale. More >>

Cooley is advising FibroGen on its $167.7 million initial public offering. With a $1.04 billion valuation, this is the largest biotech IPO by market cap since 2002. More >>

Simpson Thacher represented the underwriters, led by Goldman, Sachs & Co. and Deutsche Bank AG, London Branch, in connection with Apple Inc.’s first registered public offering of euro-denominated notes. Apple Inc. offered €1.4 billion aggregate principal amount of 1.000% notes due 2022 and €1.4 billion aggregate principal amount of 1.625% notes due 2026. The notes will be listed on the New York Stock Exchange. The net proceeds from the offering will be used for general corporate purposes, including repurchases of common stock and payment of dividends under Apple Inc.’s program to return capital to shareholders, funding for working capital, capital expenditures, acquisitions and repayment of short-term debt. More >>